![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » DURECT INITIATES TRIAL OF ORADUR-BASED DRUG CANDIDATE
DURECT INITIATES TRIAL OF ORADUR-BASED DRUG CANDIDATE
August 2, 2006
Durect has begun a trial of a new Oradur-based opioid drug candidate, the second such drug to enter clinical testing by King Pharmaceuticals, the company that will be commercializing the drug if approved, and Pain Therapeutics, the licensee of the rights to the drug and other Oradur-based products incorporating oxycodone and three other opioid compounds.
Oradur sustained-released oral gel capsule technology can also be found in Remoxy and the other drugs stemming from the King-Pain Therapeutics alliance. The technology uses a high-viscosity base component, Saber, to provide sustained release of active ingredients for a period of from 12 to 24 hours of drug delivery. This formulation may have the added benefit of being less prone to abuse than other controlled-release pain drugs on the market.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct